Danocrine Disease Interactions

The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present. Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.

The use of danazol is contraindicated in patients with androgen- dependent tumors.

The use of danazol is contraindicated in patients with severe hepatic impairment. Danazol is metabolized by the liver to inactive forms. Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction. Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.

Danazol is contraindicated in patients with marked impaired cardiac function.

Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral or papilledema and/or intracranial hypertension.

The use of danazol is contraindicated in patients with porphyria. Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.